Click here to get full coverage on Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq

Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation  Nasdaq

Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq

Click here to get full coverage on Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - Yahoo Finance

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High?  Yahoo Finance

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - Yahoo Finance

Click here to get full coverage on Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat

Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer  MarketBeat

Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat

Click here to get full coverage on Detecting support and resistance levels for KROS - Analyst Downgrade & Expert Curated Trade Ideas - newser.com

Detecting support and resistance levels for KROS - Analyst Downgrade & Expert Curated Trade Ideas  newser.com

Detecting support and resistance levels for KROS - Analyst Downgrade & Expert Curated Trade Ideas - newser.com

Click here to get full coverage on KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig - GuruFocus

KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig  GuruFocus

KROS: Wells Fargo Lowers Price Target to $23, Maintains Overweig - GuruFocus

Click here to get full coverage on New Analyst Forecast: $KROS Given $16.0 Price Target - Quiver Quantitative

New Analyst Forecast: $KROS Given $16.0 Price Target  Quiver Quantitative

New Analyst Forecast: $KROS Given $16.0 Price Target - Quiver Quantitative

Click here to get full coverage on Can KROS stock attract ESG capital inflows - Weekly Investment Recap & Free Community Consensus Stock Picks - Fundação Cultural do Pará

Can KROS stock attract ESG capital inflows - Weekly Investment Recap & Free Community Consensus Stock Picks  Fundação Cultural do Pará

Can KROS stock attract ESG capital inflows - Weekly Investment Recap & Free Community Consensus Stock Picks - Fundação Cultural do Pará

Click here to get full coverage on Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy - Ole Miss Athletics

Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy  Ole Miss Athletics

Jason Kros - Men's Tennis Coach - Ole Miss Athletics - Hotty Toddy - Ole Miss Athletics

Click here to get full coverage on $194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan

$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025  Stock Titan

$194.4M Tender Offer — Keros Therapeutics to Repurchase at $17.75; Part of $375M Program. Expires Nov. 18, 2025 - Stock Titan

Click here to get full coverage on Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation - Nasdaq

Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation  Nasdaq

Wells Fargo Maintains Keros Therapeutics (KROS) Overweight Recommendation - Nasdaq

Click here to get full coverage on Joseph David Kross - Beaver County Times

Joseph David Kross  Beaver County Times

Joseph David Kross - Beaver County Times

Click here to get full coverage on Killer Kross vs. Matt Riddle Announced for Nov 20 in Charleston - mlw.com

Killer Kross vs. Matt Riddle Announced for Nov 20 in Charleston  mlw.com

Killer Kross vs. Matt Riddle Announced for Nov 20 in Charleston - mlw.com

Click here to get full coverage on Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates  Yahoo Finance

Earnings Update: Keros Therapeutics, Inc. (NASDAQ:KROS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Click here to get full coverage on Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat

Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00  MarketBeat

Wells Fargo & Company Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat

Click here to get full coverage on Can KROS stock hit analyst price targets - 2025 Technical Patterns & Precise Buy Zone Identification - newser.com

Can KROS stock hit analyst price targets - 2025 Technical Patterns & Precise Buy Zone Identification  newser.com

Can KROS stock hit analyst price targets - 2025 Technical Patterns & Precise Buy Zone Identification - newser.com

Click here to get full coverage on Men’s Tennis Adds Jason Kros as Assistant Coach - Ole Miss Athletics

Men’s Tennis Adds Jason Kros as Assistant Coach  Ole Miss Athletics

Men’s Tennis Adds Jason Kros as Assistant Coach - Ole Miss Athletics

Click here to get full coverage on Why retail investors favor KROS stock - Earnings Miss & Capital Efficient Trading Techniques - Fundação Cultural do Pará

Why retail investors favor KROS stock - Earnings Miss & Capital Efficient Trading Techniques  Fundação Cultural do Pará

Why retail investors favor KROS stock - Earnings Miss & Capital Efficient Trading Techniques - Fundação Cultural do Pará

Click here to get full coverage on KROS vs. ARGX: Which Stock Is the Better Value Option? - Nasdaq

KROS vs. ARGX: Which Stock Is the Better Value Option?  Nasdaq

KROS vs. ARGX: Which Stock Is the Better Value Option? - Nasdaq

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Click here to get full coverage on What is HC Wainwright's Estimate for KROS FY2025 Earnings? - MarketBeat

What is HC Wainwright's Estimate for KROS FY2025 Earnings?  MarketBeat

What is HC Wainwright's Estimate for KROS FY2025 Earnings? - MarketBeat

Click here to get full coverage on KROS: Takeda deal drove $243.7M revenue and $110.5M net income; $375M capital return plan announced - TradingView

KROS: Takeda deal drove $243.7M revenue and $110.5M net income; $375M capital return plan announced  TradingView

KROS: Takeda deal drove $243.7M revenue and $110.5M net income; $375M capital return plan announced - TradingView

Click here to get full coverage on Released WWE Stars Karrion Kross and Scarlett Share Surprising Career Update - Newsweek

Released WWE Stars Karrion Kross and Scarlett Share Surprising Career Update  Newsweek

Released WWE Stars Karrion Kross and Scarlett Share Surprising Career Update - Newsweek

Click here to get full coverage on Keros Therapeutics (NASDAQ:KROS) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat

Keros Therapeutics (NASDAQ:KROS) Stock Price Expected to Rise, Wedbush Analyst Says  MarketBeat

Keros Therapeutics (NASDAQ:KROS) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat

Click here to get full coverage on Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Hold" by Analysts  MarketBeat

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Hold" by Analysts - MarketBeat

Click here to get full coverage on PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin - Clinton Herald

PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin  Clinton Herald

PHOTOS: KROS hosts 'Voice of the Hawkkeyes' Gary Dolphin - Clinton Herald

Click here to get full coverage on 'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers - KETV

'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers  KETV

'A beer for everybody': Beer brewed in La Vista named official craft beer of the Huskers - KETV

Click here to get full coverage on Insider Sale: 10% owner at $KROS Sells 4,391,237 Shares | KROS Stock News - Quiver Quantitative

Insider Sale: 10% owner at $KROS Sells 4,391,237 Shares | KROS Stock News  Quiver Quantitative

Insider Sale: 10% owner at $KROS Sells 4,391,237 Shares | KROS Stock News - Quiver Quantitative

Click here to get full coverage on Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance

Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year  Yahoo Finance

Investors in Keros Therapeutics (NASDAQ:KROS) have unfortunately lost 72% over the last year - Yahoo Finance

Click here to get full coverage on KROS vs. EXAS: Which Stock Should Value Investors Buy Now? - Yahoo Finance

KROS vs. EXAS: Which Stock Should Value Investors Buy Now?  Yahoo Finance

KROS vs. EXAS: Which Stock Should Value Investors Buy Now? - Yahoo Finance

Click here to get full coverage on KROS Surpasses Revenue Expectations and Advances Clinical Trials - GuruFocus

KROS Surpasses Revenue Expectations and Advances Clinical Trials  GuruFocus

KROS Surpasses Revenue Expectations and Advances Clinical Trials - GuruFocus

Click here to get full coverage on $375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025 - Stock Titan

$375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025  Stock Titan

$375M Capital Return: Keros Therapeutics repurchases $181M, plans $194M tender offer by Oct 2025 - Stock Titan

Click here to get full coverage on Largest Shareholder (13.3%) Confronts Keros Board Over Delayed $375M Capital Return and Strategic Direction - Stock Titan

Largest Shareholder (13.3%) Confronts Keros Board Over Delayed $375M Capital Return and Strategic Direction  Stock Titan

Largest Shareholder (13.3%) Confronts Keros Board Over Delayed $375M Capital Return and Strategic Direction - Stock Titan

Click here to get full coverage on Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m  Investing.com

Adar1 partners sells Keros Therapeutics (KROS) shares worth $95.6m - Investing.com

Click here to get full coverage on Killer Kross & Scarlett Return November 20 LIVE in Charleston, SC - mlw.com

Killer Kross & Scarlett Return November 20 LIVE in Charleston, SC  mlw.com

Killer Kross & Scarlett Return November 20 LIVE in Charleston, SC - mlw.com

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial - Yahoo Finance

Click here to get full coverage on Karrion Kross Makes Heartbreaking Confession About WWE Departure - Newsweek

Karrion Kross Makes Heartbreaking Confession About WWE Departure  Newsweek

Karrion Kross Makes Heartbreaking Confession About WWE Departure - Newsweek

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates  Yahoo Finance

Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on Keros Therapeutics (KROS) Launches $194.4 Million Stock Buyback - GuruFocus

Keros Therapeutics (KROS) Launches $194.4 Million Stock Buyback  GuruFocus

Keros Therapeutics (KROS) Launches $194.4 Million Stock Buyback - GuruFocus

Click here to get full coverage on Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m - Investing.com

Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m  Investing.com

Pontifax funds sell Keros Therapeutics (KROS) shares for $84.97m - Investing.com

Click here to get full coverage on Clinical-Stage Biotech Keros Therapeutics Featured at Wells Fargo and H.C. Wainwright Healthcare Events - Stock Titan

Clinical-Stage Biotech Keros Therapeutics Featured at Wells Fargo and H.C. Wainwright Healthcare Events  Stock Titan

Clinical-Stage Biotech Keros Therapeutics Featured at Wells Fargo and H.C. Wainwright Healthcare Events - Stock Titan

Click here to get full coverage on MSOC: Aitken, Kross nab first OVC weekly honors of 2025 - Houston Christian University Athletics

MSOC: Aitken, Kross nab first OVC weekly honors of 2025  Houston Christian University Athletics

MSOC: Aitken, Kross nab first OVC weekly honors of 2025 - Houston Christian University Athletics

Click here to get full coverage on A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $16 to $20 - 富途牛牛

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $16 to $20  富途牛牛

A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $16 to $20 - 富途牛牛

Click here to get full coverage on WWE Fans Claim Debut SmackDown Entrance Copied Karrion Kross - Newsweek

WWE Fans Claim Debut SmackDown Entrance Copied Karrion Kross  Newsweek

WWE Fans Claim Debut SmackDown Entrance Copied Karrion Kross - Newsweek

Click here to get full coverage on KROS's Gary Determan still has love for Radio in 50th Season - Clinton Herald

KROS's Gary Determan still has love for Radio in 50th Season  Clinton Herald

KROS's Gary Determan still has love for Radio in 50th Season - Clinton Herald

Click here to get full coverage on Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates - Nasdaq

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates  Nasdaq

Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates - Nasdaq

Click here to get full coverage on Killer Kross And Scarlett Manage Their Business On The Indies With Wrestling Fans In Mind (Exclusive) - Sports Illustrated

Killer Kross And Scarlett Manage Their Business On The Indies With Wrestling Fans In Mind (Exclusive)  Sports Illustrated

Killer Kross And Scarlett Manage Their Business On The Indies With Wrestling Fans In Mind (Exclusive) - Sports Illustrated

Click here to get full coverage on Keros Therapeutics (KROS) Initiates $194.4M Stock Buyback Progra - GuruFocus

Keros Therapeutics (KROS) Initiates $194.4M Stock Buyback Progra  GuruFocus

Keros Therapeutics (KROS) Initiates $194.4M Stock Buyback Progra - GuruFocus

Click here to get full coverage on Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS)  Seeking Alpha

Keros Therapeutics: A Potential Dart Throw (NASDAQ:KROS) - Seeking Alpha

Click here to get full coverage on Keros Therapeutics (KROS) Announces Share Repurchase Agreements - GuruFocus

Keros Therapeutics (KROS) Announces Share Repurchase Agreements  GuruFocus

Keros Therapeutics (KROS) Announces Share Repurchase Agreements - GuruFocus

Click here to get full coverage on Chaotic Brilliance of a Heavenly Nature: The Melvins, Redd Kross and SERVICE at The Vogue 09/20/2025 - NUVO.net

Chaotic Brilliance of a Heavenly Nature: The Melvins, Redd Kross and SERVICE at The Vogue 09/20/2025  NUVO.net

Chaotic Brilliance of a Heavenly Nature: The Melvins, Redd Kross and SERVICE at The Vogue 09/20/2025 - NUVO.net

Click here to get full coverage on “Greatest day of my life” – Former WWE star Karrion Kross reveals his mother’s cancer-free status in hear - Times of India

“Greatest day of my life” – Former WWE star Karrion Kross reveals his mother’s cancer-free status in hear  Times of India

“Greatest day of my life” – Former WWE star Karrion Kross reveals his mother’s cancer-free status in hear - Times of India

Click here to get full coverage on Indian Reality TV Gets Korean Makeover as Kross Pictures Unveils Four-Format Slate at Busan Market (EXCLUSIVE) - Variety

Indian Reality TV Gets Korean Makeover as Kross Pictures Unveils Four-Format Slate at Busan Market (EXCLUSIVE)  Variety

Indian Reality TV Gets Korean Makeover as Kross Pictures Unveils Four-Format Slate at Busan Market (EXCLUSIVE) - Variety

Click here to get full coverage on Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point - simplywall.st

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point  simplywall.st

Keros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting Point - simplywall.st

Click here to get full coverage on This Weekly Event Drives Kros Strain Consumers to its Taproom on Fridays - The Brewer Magazine

This Weekly Event Drives Kros Strain Consumers to its Taproom on Fridays  The Brewer Magazine

This Weekly Event Drives Kros Strain Consumers to its Taproom on Fridays - The Brewer Magazine

Click here to get full coverage on Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches - Stock Titan

Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches  Stock Titan

Keros Transforms Pipeline: Focuses All Resources on Promising DMD Drug KER-065 as Phase 2 Trial Approaches - Stock Titan

Click here to get full coverage on Build-Outs Of Coffee: Kross Coffee Roasters In Chania, Greece - Sprudge

Build-Outs Of Coffee: Kross Coffee Roasters In Chania, Greece  Sprudge

Build-Outs Of Coffee: Kross Coffee Roasters In Chania, Greece - Sprudge

Click here to get full coverage on Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified - simplywall.st

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified  simplywall.st

Improved Revenues Required Before Keros Therapeutics, Inc. (NASDAQ:KROS) Stock's 44% Jump Looks Justified - simplywall.st

Click here to get full coverage on What catalysts could drive KROS stock higher - Market Growth Report & Short-Term High Return Strategies - Fundação Cultural do Pará

What catalysts could drive KROS stock higher - Market Growth Report & Short-Term High Return Strategies  Fundação Cultural do Pará

What catalysts could drive KROS stock higher - Market Growth Report & Short-Term High Return Strategies - Fundação Cultural do Pará

Click here to get full coverage on Josh Kross - Tablet Magazine

Josh Kross - Tablet Magazine

Click here to get full coverage on Karrion Kross and Scarlett Moved to WWE Alumni Page, Scarlett Releases Statement - VICE

Karrion Kross and Scarlett Moved to WWE Alumni Page, Scarlett Releases Statement  VICE

Karrion Kross and Scarlett Moved to WWE Alumni Page, Scarlett Releases Statement - VICE

Click here to get full coverage on Karrion Kross Sends Message To Fans Questioning Legitimacy Of WWE Exit - Newsweek

Karrion Kross Sends Message To Fans Questioning Legitimacy Of WWE Exit  Newsweek

Karrion Kross Sends Message To Fans Questioning Legitimacy Of WWE Exit - Newsweek

Click here to get full coverage on Karrion Kross Reveals WWE Gave Him Shocking Contract Ultimatum - Newsweek

Karrion Kross Reveals WWE Gave Him Shocking Contract Ultimatum  Newsweek

Karrion Kross Reveals WWE Gave Him Shocking Contract Ultimatum - Newsweek

Click here to get full coverage on Karrion Kross Breaks Silence On WWE Departure - Newsweek

Karrion Kross Breaks Silence On WWE Departure  Newsweek

Karrion Kross Breaks Silence On WWE Departure - Newsweek

Click here to get full coverage on Karrion Kross And Scarlett's First Announced Appearance After WWE Exit Revealed - Sports Illustrated

Karrion Kross And Scarlett's First Announced Appearance After WWE Exit Revealed  Sports Illustrated

Karrion Kross And Scarlett's First Announced Appearance After WWE Exit Revealed - Sports Illustrated

Click here to get full coverage on Drew McIntyre Breaks Silence on Karrion Kross’ WWE Departure - Newsweek

Drew McIntyre Breaks Silence on Karrion Kross’ WWE Departure  Newsweek

Drew McIntyre Breaks Silence on Karrion Kross’ WWE Departure - Newsweek

Click here to get full coverage on Karrion Kross Admits That His WWE Release "Was All One Big Work" - With An Unexpected Twist - TheRingReport.com

Karrion Kross Admits That His WWE Release "Was All One Big Work" - With An Unexpected Twist  TheRingReport.com

Karrion Kross Admits That His WWE Release "Was All One Big Work" - With An Unexpected Twist - TheRingReport.com

Click here to get full coverage on New Developments Regarding Karrion Kross As WWE Contract Nears Expiration - Sports Illustrated

New Developments Regarding Karrion Kross As WWE Contract Nears Expiration  Sports Illustrated

New Developments Regarding Karrion Kross As WWE Contract Nears Expiration - Sports Illustrated

Click here to get full coverage on Karrion Kross says WWE pulled contract offer after 24 hours: 'We still want to work it out' - CBS Sports

Karrion Kross says WWE pulled contract offer after 24 hours: 'We still want to work it out'  CBS Sports

KROS

Price Chart

Key Statistics

Technicals

About KROS

Latest News

Oppenheimer Reiterates Keros Therapeutics (KROS) Outperform Recommendation - Nasdaq

Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - Yahoo Finance

Keros Therapeutics' (KROS) Outperform Rating Reiterated at Oppenheimer - MarketBeat

Advanced Charts

Top Gainers

Top Losers